Ocular Therapeutix (OCUL) FCF Margin (2014 - 2026)

Ocular Therapeutix's FCF Margin history runs 13 years deep, the most recent figure standing at 624.2% for Q1 2026.

• On a quarterly basis, FCF Margin fell 18857.0% year-over-year to 624.2% in Q1 2026; TTM through Mar 2026 was 456.61%, a 20972.0% decrease from a year earlier, with the FY2025 full-year figure at 417.5%, down 20596.0% from the prior year.
• FCF Margin retreated to 624.2% in Q1 2026 per OCUL's latest filing, from 430.85% in the prior quarter.
• Across five years, FCF Margin topped out at 17.44% in Q3 2023 and bottomed at 624.2% in Q1 2026.
• The 5-year median for FCF Margin is 191.03% (2023), against an average of 244.01%.
• Across the five-year window, FCF Margin soared 9459 bps in 2022 and slumped 27010 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 126.93% in 2022, then sank by 51 bps to 191.03% in 2023, then retreated by 21 bps to 231.09% in 2024, then tumbled by 86 bps to 430.85% in 2025, then tumbled by 45 bps to 624.2% in 2026.
• Per Business Quant, the three latest OCUL FCF Margin figures stand at 624.2% (Q1 2026), 430.85% (Q4 2025), and 389.98% (Q3 2025).